


**Audited Financial Results for the 4<sup>th</sup> Quarter and Financial Year Ended 31<sup>st</sup> March 2012**

<b>PART I</b>						
<b>(Rs/in Lakhs)</b>						
	<b>Particulars</b>	<b>3 months ended (31/03/2012)</b>	<b>Preceding 3 months ended (31/12/2011)</b>	<b>Corresponding 3 months ended (31/03/2011) in the previous year</b>	<b>Year to date figures for current period ended (31/03/2012)</b>	<b>Year to date figures for the previous year ended (31/03/2011)</b>
	<b>(Refer Notes Below)</b>	<b>Audited</b>	<b>Unaudited</b>	<b>Audited</b>	<b>Audited</b>	<b>Audited</b>
<b>1</b>	<b>Income from operations</b>					
	(a) Net sales/income from operations (Net of excise duty)	1134.21	1140.56	945.06	4555.75	5599.51
	(b) Other operating income	0.00	0.00	0.00	0.00	0.00
	<b>Total income from operations (net)</b>	<b>1134.21</b>	<b>1140.56</b>	<b>945.06</b>	<b>4555.75</b>	<b>5599.51</b>
<b>2</b>	<b>Expenses</b>					
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	1089.07	1089.90	890.29	4358.74	5094.09
	(c) Changes in inventories of finished goods, work-in-progress and stock- in-trade	-0.10	0.00	13.83	9.41	302.45
	(d) Employee benefits expense	5.64	6.34	7.14	25.40	30.04
	(e) Depreciation and amortisation expense	9.30	9.30	10.26	37.20	41.06
	(f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	13.51	14.95	11.15	55.44	53.09
	<b>Total expenses</b>	<b>1117.42</b>	<b>1120.49</b>	<b>932.67</b>	<b>4486.19</b>	<b>5520.73</b>
<b>3</b>	<b>Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>16.79</b>	<b>20.07</b>	<b>12.39</b>	<b>69.56</b>	<b>78.78</b>
<b>4</b>	<b>Other income</b>	<b>2.02</b>	<b>3.06</b>	<b>6.64</b>	<b>11.03</b>	<b>12.62</b>
<b>5</b>	<b>Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>80.59</b>	<b>91.40</b>
<b>6</b>	<b>Finance costs</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>7</b>	<b>Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>80.59</b>	<b>91.40</b>
<b>8</b>	<b>Exceptional items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>9</b>	<b>Profit / (Loss) from ordinary activities before tax(7+8)</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>80.59</b>	<b>91.40</b>
<b>10</b>	<b>Tax expense</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>10.29</b>	<b>-0.08</b>
<b>11</b>	<b>Net Profit/(Loss) from ordinary activities after tax(9+10)</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>70.30</b>	<b>91.48</b>
<b>12</b>	<b>Extraordinary items</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>13</b>	<b>Net Profit / (Loss) for the period (11 + 12)</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>70.30</b>	<b>91.48</b>
<b>14</b>	<b>Paid-up equity share capital</b>	<b>1099.20</b>	<b>1099.20</b>	<b>1099.20</b>	<b>1099.20</b>	<b>1099.20</b>
	(Face Value of the Share shall be indicated)(Rs.)	1.00	1.00	1.00	1.00	1.00
<b>15</b>	<b>Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year</b>				<b>734.72</b>	<b>664.42</b>
<b>16</b>	<b>Earnings per share (not annualised):</b>					
	(a) Basic	0.02	0.02	0.02	0.06	0.08
	(b) Diluted	0.02	0.02	0.02	0.06	0.08


**Corporate Office :**

 A-56/A Lajpat Nagar - II, 1st Floor, New Delhi - 110 024  
 Tel: +91-11-41720778 Fax: +91-11-29847741

Email: info@mavensbiotech.com

Website: www.mavensbiotech.com

**Registered Office :**


 Sagar Estate, Suite No. 21, Grd, 2 N. C. Dutta Sarani,  
 Kolkata - 700 001 Tel: +91-33-22623056

PART II						
Select Information for the 4th Quarter and Year Ended 31/03/2012						
	Particulars	3 months ended (31/03/2012)	Preceding 3 months ended (31/12/2011)	Corresponding 3 months ended (31/03/2011) In the previous year	Year to date figures for current year ended (31/03/2012)	Year to date figures for previous year ended (31/03/2011)
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>					
1	Public shareholding					
	- Number of shares	74700010	74700010	74700010	74700010	74700010
	- Percentage of shareholding	67.96%	67.96%	67.96%	67.96%	67.96%
2	Promoters and Promoter Group Shareholding **					
a)	Pledged / Encumbered					
	- Number of shares	0	0	0	0	0
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0%	0%	0%	0%	0%
	- Percentage of shares (as a % of the total share capital of the company)	0%	0%	0%	0%	0%
b)	Non - encumbered					
	- Number of shares	35219990	35219990	35219990	35219990	35219990
	- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100%	100%	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the company)	32.04%	32.04%	32.04%	32.04%	32.04%

	Particulars	3 months ended (31/03/2012)
<b>B</b>	<b>INVESTOR COMPLAINTS</b>	
	Pending at the beginning of the quarter	0
	Received during the quarter	2
	Disposed of during the quarter	2
	Remaining unresolved at the end of the quarter	0

Quarterly Reporting Segmentwise Revenue, Results and Capital Employed under Clause 41 of the Listing Agreement

(Rs In Lacs)					
Particulars	3 Months ended 31/03/2012	3 Months ended 31/12/2011	3 Months ended 31/03/2011	Financial Year ended 31/03/2012	Financial Year ended 31/03/2011
	Audited	Unaudited	Audited	Audited	Audited
(Net Sale/ income from each segment)					
<b>Segment Revenue</b>					
(a) Sale of Commodities	1134.13	1139.54	945.06	4552.72	5595.55
(b) IT Activities	0.08	1.02	0.00	3.03	3.96
Total	1134.21	1140.56	945.06	4555.75	5599.51
Less : Inter Segment Revenue	0.00	0.00	0.00	0.00	0.00
<b>Net Sales/ Income from operations</b>	<b>1134.21</b>	<b>1140.56</b>	<b>945.06</b>	<b>4555.75</b>	<b>5599.51</b>
<b>Segment Results</b>					
(Profit/Loss before tax and interest from each segment)					
(a) Sale of Commodities	18.84	23.11	21.12	80.57	100.67
(b) IT Activities	0.02	0.07	0.00	0.24	0.14
Less : Inter Segment Income	0.00	0.00	0.00	0.00	0.00
Less: Unallocable Expenditure	0.05	0.05	2.09	0.22	9.41
<b>PBT</b>	<b>18.81</b>	<b>23.13</b>	<b>19.03</b>	<b>80.59</b>	<b>91.40</b>



Corporate Office :

A-56/A Lajpat Nagar - II, 1st Floor, New Delhi - 110 024  
Tel: +91-11-41720778 Fax: +91-11-29847741

Email: info@mavensbiotech.com - Website: www.mavensbiotech.com

Registered Office :

Sagar Estate, Suite No. 21, Grd, 2 N. C. Dutta Sarani,  
Kolkata - 700 001 Tel: +91-33-22623056


2. Annexure-IX of Clause 41 shall be substituted with the following, viz.,  
**Clause 41 of the Listing Agreement For Companies (Other than Banks)**

Standalone / Consolidated Statement of		As at current year ended (31/03/2012)	As at (previous year end) (31/03/2011)
Particulars			
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Shareholders' funds</b>		
	(a) Share capital	109,920,000	109,920,000
	(b) Reserves and surplus	73,472,287	66,441,777
	<b>Sub-total - Shareholders' funds</b>	<b>183,392,287</b>	<b>176,361,777</b>
2	<b>Non-current liabilities</b>		
	(a) Deferred tax liabilities (net)	230,158	376,607
	<b>Sub-total - Non-current liabilities</b>	<b>230,158</b>	<b>376,607</b>
3	<b>Current liabilities</b>		
	(a) Trade payables	1,905,437	1,834,752
	(b) Other current liabilities	1,715,622	1,725,092
	(c) Short-term provisions	690,000	131,000
	<b>Sub-total - Current liabilities</b>	<b>4,311,059</b>	<b>3,690,844</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>187,933,504</b>	<b>180,429,228</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non-current assets</b>		
	(a) Fixed assets		
	(i) Tangible Assets	52,416,017	52,871,149
	(ii) Capital Work in Progress	14,415,803	13,177,265
	(b) Non-current investments	4,176,000	2,475,160
	(c) Long-term loans and advances	43,730,405	42,132,200
	<b>Sub-total - Non-current assets</b>	<b>114,738,225</b>	<b>110,655,774</b>
2	<b>Current assets</b>		
	(a) Inventories	30,658,739	31,599,395
	(b) Trade receivables	40,637,096	35,388,434
	(c) Cash and cash equivalents	1,899,444	2,785,625
	<b>Sub-total - Current assets</b>	<b>73,195,279</b>	<b>69,773,454</b>
	<b>TOTAL - ASSETS</b>	<b>187,933,504</b>	<b>180,429,228</b>

**Notes:**

- The above Audited financial results for the quarter ended 31.03.2012 and the Audited financial results for the year ended 31.03.2012 were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 30<sup>th</sup> May 2012
- Segment Revenue: Revenue for this quarter/ year comes from two activities, i.e., Sale of Commodities & Agro Products (including Agriculture & Biotech Business, Pharma Business) and IT Business.
- Profit after tax is Rs.70.30 lacs. In compliance of AS-22, deferred tax on timing difference for the year has been indicated at Rs. (1.46) lacs.
- Figures of the previous period have been regrouped wherever necessary.

Place: Kolkata  
 Date: 30/05/2012



By behalf of the Board  
 For MAVENS Biotech Limited  
 Sd/-  
 Director